ANGIMMUNE LLC has a total of 12 patent applications. It decreased the IP activity by 66.0%. Its first patent ever was published in 2013. It filed its patents most often in EPO (European Patent Office), United States and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are UNITED NEUROSCIENCE, GUSS BENGT and IMMUNOMIC THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 3 | |
#2 | United States | 3 | |
#3 | Canada | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | China | 1 | |
#6 | India | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology | |
#4 | Medical technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Climate change adaptation technologies | |
#5 | Electrotherapy |
# | Name | Total Patents |
---|---|---|
#1 | Neville David M Jr | 6 |
#2 | Neville David M | 5 |
#3 | Liu Yuan Yi | 1 |
#4 | Neville Jr David M | 1 |
Publication | Filing date | Title |
---|---|---|
EP3496707A1 | Treatment of cancer using a combination of immunomodulation and check point inhibitors | |
CN105050625A | Immunomodulation by anti-cd3 immunotoxins to treat cancers not uniformly bearing surface cd3 |